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A B S T R A C T
Background: Drug resistance development is an expected problem during treatment with protease
inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated
variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of
this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C
(HCV) drug associated resistance to oral antivirals.
Materials and methods: 178 antiviral-naı¨ve patients infected with HCV genotype 1 were selected from
27 clinical centers of various geographical regions in Turkey and included in the current study. The basal
NS3 Pls resistance mutations of these patients were analyzed.
Results: In 33 (18.5%) of the patients included in the study, at least one mutation pattern that can cause
drug resistance was identiﬁed. The most frequently detected mutation pattern was T54S while R109K
was the second most frequently detected. Following a more general examination of the patients studied,
telaprevir (TVR) resistance in 27 patients (15.2%), boceprevir (BOC) resistance in 26 (14.6%) patients,
simeprevir (SMV) resistance in 11 (6.2%) patients and faldaprevir resistance in 13 (7.3%) patients were
detected. Our investigation also revealed that rebound developed in the presence of a Q80K mutation and
amongst two V55A mutations following treatment with TVR, while no response to treatment was
detected in a patient with a R55K mutation.
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nc-nd/4.0/).1. Background
Hepatitis C virus (HCV), has a 9.6 kb-long genome and is a
single-stranded RNA virus.1,2 There are seven different HCV
genotypes and more than 90 subtypes.3 The most frequently
encountered HCV genotypes worldwide are genotypes 1, 2 and
3. Similarly in Turkey, HCV genotype 1 infection is the most
commonly detected HCV infection type.4,5 HCV genotyping is
critical for selecting the treatment type, predicting the possible
response to the treatment and also in deciding the duration of the
treatment.6,7
In chronic hepatitis C (CHC) infections, and in situations where
the virus is not integrated into the host cell genome, the targets
that the treatment interacts with is often regarded as a ‘cure’ unlike
that in hepatitis B and Human Immunodeﬁciency Virus infection
treatments.8 Until now, the available standard treatment admin-
istered using pegylated interferon (PEG-IFN) and ribavirin (RBV)
has had limited effects with signiﬁcant associated side effects.9,10
However, CHC treatment options have been gradually increasing
along with the use of various direct-acting antiviral agents (DAAs).
NS3/4A serine protease, NS5B polymerase and NS5A protein (the
non-structural proteins necessary for virus replication), are three
important main drug targets for DAAs.11,12 The ﬁrst generation
NS3/4A PIs telaprevir (TVR) and boceprevir (BOC) both inhibit the
NS3/4A serine protease enzyme required for HCV replication.13,14
In 2011, TVR and BOC were approved to be used in combination
with PEG-IFN and RBV for treatment of HCV genotype 1 infection.
Although sustained virological response (SVR) rates have increased
with these new regimes, treatment compliance has considerably
decreased due to the increase in drug load and side effects. On the
other hand, when SMV, a second generation PI is used in
combination with PEG-IFN/RBV similar SVR rates can be obtained.
HCV has a high replication capacity (1010-12 virion/day) and its
polymerase activity does not have error-correcting ability.2,8,15
Formation of variants due to mutations occurring during viral
replication may lead to a decrease in the sensitivity to antiviral
agents.16–18 Treatment with TVR and BOC, may result in resistance
development due to the fact that they are low genetic barrier
antiviral drugs.19 Resistant variants may also occur naturally and
may be found prior to the commencement of treatment.8,13,14,20,21
However, the clinical impact of basal resistance still remains
unclear.
According to The World Health Organization’s 2013 HCV
disease burden report, Turkey has been categorized together with
countries which form part of North Africa and the Middle East. The
HCV prevalence amongst countries in these regions has been
reported as 3.2 – 4.1%.22 However, in recent studies conducted in
Turkey anti-HCV positivity rates vary between 0.1-1%.23,24 In
Turkey, where there is mid-level HCV prevalence, PIs, TVR and BOC,
have been in use since 2013. The use of SMV in Turkey however is
yet to occur. Therefore, the data-based in Turkey with regards to
antiviral use and the mutations that may occur as a consequence of
their use is yet to be available.
The purpose of the current study was to determine PI resistance
at the molecular level in CHC patients in Turkey infected with
genotype 1, and to identify clinical reﬂections of drug resistance
mutations.2. Materials and methods
2.1. Patient population
The present study was conducted between May 2012 – March
2015, and included 178 HCV genotype 1 infected patients, who
were diagnosed from across 27 infectious disease departments
from 21 cities within Turkey.
Clinic and laboratory characteristics of the patients are shown in
Table 1. The study was approved by the local ethics committee
(Clinical Research Ethics Committee of Kocaeli University, KOU
KAEK 2012/12 and written consent was obtained from each patient.
All of the patients were categorized as hepatitis C chronic
carriers according to the European Association for the Study of the
Liver Clinical Practice Guidelines.25 Blood samples with K2EDTA
were immediately separated by centrifugation, aliquoted, and kept
at -80 8C until required. The presence of Anti-HCV antibodies were
tested for on all samples which were anti-HCV positive through
ELISA testing, using a commercially available microparticle
enzyme immunoassay kit (Axsym; Abbott Laboratories, Abbott
Park, IL, USA and Elecsys, Roche Diagnostics, Mannheim, Germany)
2.2. HCV RNA isolation and detection
Magnetic particle-based HCV RNA extraction and HCV RNA
detection and quantiﬁcation were performed using commercial
real-time PCR assay – QIAsypmhony + Rotorgene Q/artus HCV QS-
RGQ (Qiagen GmBH, Hilden, Germany), COBAS Ampliprep/COBAS
TaqMan HCV Test (Roche Molecular Systems, Inc. Pleasanton, CA,
USA) and Abbott M2000 SP/Abbott RealTime HCV Ampliﬁcation Kit
(Abbott Molecular Inc. Des Plaines, IL, USA).
2.3. HCV NS3 region sequencing
Genotypic resistance testing was performed by population
sequencing of the viral protease (codon 32 -185) using an in-house
method with a commercial kit (Bosphore HCV drug resistance
mutation sequencing kit v1.0, (Anatolia Geneworks, Istanbul,
Turkey). The RT-PCR and the cycle sequencing thermal protocols
were applied according to the manufacturer’s instructions. PCR
products were puriﬁed using the Bosphore PCR Product Puriﬁca-
tion Spin Kit (Anatolia Geneworks, Istanbul, Turkey) and sequenc-
ing was performed via Beckman Coulter CEQ 8000 Genetic Analysis
System and the CEQ 8000 Genetic Analysis System Version
9 software (Beckman Coulter Inc., Brea, CA, USA).
2.4. Drug resistance mutation detection
Drug resistance mutation was analyzed by The Genafor/Arevir-
geno2pheno drug resistance tool (Center of Advanced European
Studies and Research, Bonn, Germany, http://coreceptor.bioinf.
mpi-inf.mpg.de/). HCV D90208 was used as a reference strain for
the HCV NS3 region.
3. Results
156 (87.6%) of the HCV genotype 1-infected patients were
infected with subtype b. Out of 57 patients examined for
Table 1
Demographic characteristics of the study patients
Characteristic Study group
Patient, n 178
Gender, F/M, n (%) 97 (54,5%)/81 (45,5%)
Age, median years (range) 56 (19 - 93)
HCV RNA, median IU/mL (range) 1.02+E7 (2.6+E3 - 1.0+E9)
ALT/AST, median U/L (range) 61 (8 - 280)/51 (6 - 220)
Sampling, region; city of Turkey Marmara; Istanbul, Kocaeli, Edirne, Bursa, Sakarya, Yalova Black Sea; Zonguldak, Giresun East Anatolia; Erzincan
Southeast Anatolia; Diyarbakir, Gaziantep, Urfa
Central Anatolia; Ankara, Kayseri, Konya, Eskisehir Aegean; Izmir, Afyonkarahisar
Mediterranean; Antalya, Mersin, Kahramanmaras
HCV genotype, n(%)
1a
1b
1
14 (7,9%)
156 (87,6%)
8 (4,4%)
Patient under haemodialysis, n(%) 10 (5,6%)
HIV Co-infection, n(%) 1 (0,6%)
IL 28B polimorphism*, n(%)
CT
CC
TT
34 (59,6%)
9 (15,8%)
14 (24,6%)
Abbreviations: F, female; M, male; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HIV, Human Immunodeﬁciency Virus
* IL28B polimorphism; rs12979860 C/T
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found to be CT, nine (15.8%) patients CC and 14 (24.6%) of them TT.
The demographic and laboratory characteristics of the patients are
shown in Table 1.
Amongst 33 (18.5%) of the 178 patients included in the current
study, PI-associated amino acid substitutions were detected. In
patients, where 22 different mutation patterns were detected, the
two most common mutation patterns identiﬁed were T54S and
R109K, respectively. Furthermore, amino acid substitutions were
associated with telaprevir (TVR) resistance in 27 patients (15.2%),
boceprevir (BOC) resistance in 26 (14.6%) patients, simeprevir
(SMV) resistance in 11 (6.2%) patients and faldaprevir resistance in
13 (7.3%) patients. The PI-associated amino acid substitutions
detected are presented in Table 2.
The patients examined were segregated into two groups; Group
one consisted of patients with no PI-associated amino acidTable 2
Drug resistance mutation pattern in the study patients (n = 33)
Mutation
pattern
Patient,
n (%)
Drug Resistance status
T54S 9 (5,1%) TVR
BOC, Faldaprevir
Potantial resistant
Resistant
V55A 3 (1,7%) TVR, BOC Resistant
Q80L 3 (1,7%) Faldaprevir Resistant
Q80H 1 (0,6%) SMV Resistant
Q80K 1 (0,6%) TVR, BOC, SMV,
Faldaprevir
Resistant
R109K 5 (2,8%) TVR, BOC, SMV Potantial resistant
R117C 1 (0,6%) TVR, BOC Potantial resistant
R117H 2 (1,1%) TVR, BOC Resistant
S122G 1 (0,6%) SMV Potantial resistant
L155I 1 (0,6%) TVR Resistant
I155L 1 (0,6%) TVR Resistant
R155K 1 (0,6%) TVR, BOC, SMV,
Faldaprevir
Resistant
R155G 1 (0,6%) TVR, BOC Resistant
R155T 1 (0,6%) TVR, BOC Resistant
A156G 1 (0,6%) BOC, SMV Resistant
A156S 1 (0,6%) TVR, BOC Resistant
A156T 1 (0,6%) TVR, BOC, SMV Resistant
G156S 2 (1,1%) TVR, BOC Resistant
I170V 1 (0,6%) TVR, BOC Resistant
I170T 1 (0,6%) BOC Resistant
N174F 1 (0,6%) TVR, BOC Resistant
N174S 3 (1,7%) TVR, BOC Potantial resistant
Telaprevir, TVR; boceprevir, BOC; simeprevir, SMV.substitution (sensitive group), while Group 2 consisted of patients
with at least one PI-associated drug resistance mutation (resistant
group). Accordingly, 145/178 (81.5%) patients formed part of the
sensitive group and 33/178 patients (18.5%) formed part of the
resistant group. 48/145 patients in the sensitive group received
one of the triple combination treatments containing TVR (n=39) or
BOC (n=9). On the other hand, 7/33 of the patients in the resistant
group received combination treatment containing TVR (Table 3).
The resistance mutation patterns amongst the resistant group
(Group1) and the results following treatment are shown in
Table 4. It became evident that a patient with a R155K mutation
is non-responsive to the treatment, furthermore viral rebound
developed during the treatment period, in one case both Q80K and
N174S mutation patterns were detected, while in two separate
cases V55A mutation patterns were detected (Table 4).
4. Discussion
In Turkey, HCV PIs drug resistance analysis was contextualized
the ﬁrst time in a surveillance study conducted at a national level
in 2013 by the Viral Hepatitis Study Group of Turkish Society of
Clinical Microbiology and Infection Diseases.26 In the currentTable 3
Treatment response according to the resistance mutation in patients
Treatment response No resistance
mutation, n = 48
On the resistance
mutation, n = 7
TVR/BOC, n(%) 39 (81,2%)/9 (18,8%) 7 (100%)/0 (0%)
Untolerated treatment
by adverse effects, n(%)
15 (31,3%) 1 (14,3%)
SVR, n(%) 26* (54,2%) 2 (28,6%)
Relapsed, n(%) 3** (6,2%) 0 (0%)
Viral Rebound, n(%) 3*** (6,2%) 3 (42,9%)
Lack of virological
response, n(%)
1 (2,1%) 1 (14,3%)
SVR, sustained virological response; TVR, telaprevir; BOC, boceprevir
* One of the sustained virological response obtained patients was a hemodialysis
patient treated with TVR, PEG-IFN alfa 2a and 200 mg/day RBV combination for
24 weeks.
** In one of the patients, according to the drug resistance analyses performed
after rebound developed during her/his telaprevir treatment, D168N (TVR possibly
resistant, BOC resistant) mutation was detected.
*** In one of the patients, drug resistance was analyzed after a relapse developed
following the telaprevir treatment and no resistance was detected.
Table 4
Telaprevir treatment response and the resistance mutation pattern detected in the patients (n = 7)
Patient no HCV genotype IL28 B polymorphism Mutation characteristic Treatment response
Pattern Resistance status Fold change
1 1b CC T54S TVR partial resistant 1.9 SVR
2 1b ND R155G TVR resistant
BOC resistant
7.4
20
SVR
3 1b CC Q80L Faldaprevir resistant 1.2 Untolerated treatment
by adverse effects
4 1a ND
R155K TVR resistant
BOC resistant
SMV resistant
Faldaprevir resistant
7.4
4.7
420
360
Lack of virological response
I170T BOC resistant 4.7
5 1a ND
Q80K TVR possibly resistant
BOC possibly resistant
SMV resistant
Faldaprevir resistant
14
Viral rebound
N174S TVR possibly resistant
BOC possibly resistant
0.8
0.5
6 1 CT V55A TVR resistant
BOC resistant
3.1
6.9
Viral rebound
7 1b ND V55A TVR resistant
BOC resistant
3.1
6.9
Viral rebound
Abbreviations; ND, not determined, SVR, sustained virological response; TVR, telaprevir; BOC, boceprevir; simeprevir, SMV.
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(18.5%) were resistant to at least one antiviral drug (Table 2). In
various other studies conducted, both in American and European
populations the percentage of DAAs-resistant variants in naive
patients infected with HCV genotype 1 has been reported as 8.6%,
and 71% in China.16,27 In another study, conducted in 2014 Chen
et al. stated that the global prevalence of DAA RAVs was at 58.7%.28
In the current study although the NS3, NS5A and NS5B regions
were analyzed RAVs were most frequently detected in the NS5A
and NS3 regions. Once the results of these studies were compared
with previous ﬁndings it became evident that the resistance rates
varied dramatically amongst countries. In the forthcoming years,
depending on the proliferation of CHC treatment with PIs, changes
in the prevalence of drug resistance mutation can also be expected.
In our study, the two most frequently detected resistance
mutations were T54S (5.1%) and R109K (2.8%). On the contrary, in a
study conducted by Ye Wang et al. S122G (56.6%), which causes
SMV resistance, was observed to be the most frequently detected
mutation.27 Our results indicate that a S122G mutation was
detected in only one patient (0.6%), furthermore the number of the
patients with resistance to DAAs TVR and BOC, (which are still in
use in Turkey), were found to be 27 (15.2%) and 26 (14.6%),
respectively. Although there have only been a limited number of
studies conducted, the percentage of the pre-treatment TVR
resistance mutations (V36L, T54A/S, V55A, Q80K/R, R155I/K/M/T,
A156S, D168Q and V170T) detected in the world is reported to be
between 4-28% 29-31. Identiﬁcation of the mutations which occur
during treatment of CHC with antivirals may be necessary in
understanding its contagiousness, comprehending its circulation
and for the surveillance of its course.
In the near future, SMV is also expected to come into use in
Turkey. In our study, the mutation patterns (Q80H, Q80K, R109K,
S122G, R155K, A156G, A156T) causing resistance to SMV was
detected in 11 (6.2%) of the xx patients examined (Table 2).
Amongst the detected mutation patterns, Q80K and R155K were of
particular interest, due to the fact that it resulted in resistance to
the entire PI drug class. In previous studies, the prevalence of Q80K
polymorphism in patients infected with HCV genotype 1a was
found to be between 22-30%, comparatively this rate was found to
be between 0.5-1% in those infected with genotype 1b.32,33 If any
Q80K mutation pattern is detected in advance in HCV type 1a
patients it is recommended not to start SMV treatment.34 In ourstudy, it was observed that a patient with a R155K mutation was
non-responsive to the treatment while a viral rebound developed
during the treatment period in a patient with a Q80K mutation
(Table 4). Our ﬁndings highlight the need for pre-treatment
examination of patients for any Q80K and R155K mutations.
Previous studies demonstrate that there is a correlation
between the pre-treatment of patients with PI mutations and
treatment with DAAs.35–37 In our study, while the SVR rate in the
sensitive group was found to be 54.2%, the SVR rate in the
resistance group was found to be 28.6%. Furthermore, while no
response to the treatment could be obtained in 2.1% of the patients
in the sensitive group the percentage of patients without any
response to the treatment amongst the resistance group was 14.3%.
Rebound developed during treatment in 42.9% of the patients in
the resistance group, while this rate was determined as 6.2% in the
sensitive group (Table 3).
Another disadvantage of HCV infection treatment with NS3/4A
serine PIs is that some associated side effects were observed in a
signiﬁcant number of patients which may lead to early termination
of the treatment.13,14,20,21 According to the evaluation of TVR
treatment, research ﬁndings obtained from a study conducted by
Aygen et al. in Turkey, revealed that early termination as a result of
side effects was observed in 9.9% of patients. This study also
revealed that the most frequent side effect resulting in early
termination was gastrointestinal associated side effects (63.6%).38
Also, in another study conducted in Kocaeli/Turkey, 26.1% of
patients could not continue TVR treatment due to side effects.39 In
our study, 16 (29.1%) out of the 55 patients who participated in the
treatment could not continue their treatment due to side effects.
Collectively these results suggest that there is a crucial need in
Turkey for new easy-to-use, effective and reliable treatment
options with a low side effect risk.
5. Conclusion
PIs resistance-associated amino acid substitutions can be
detected in DAA naive and CHC patients prior to therapy and PI
treatment, respectively. Our ﬁndings indicate that the PIs resistance-
associated amino acid substitutions can be effective in clinical. HCV
associated DAA resistance testing must remain as an integral part of
the management of DAA naı¨ve and experienced patients in Turkey.
In addition, monitoring PIs resistance - associated amino acid
E. Sargin Altunok et al. / International Journal of Infectious Diseases 50 (2016) 1–5 5substitutions can provide useful information while preparing
treatment plans and for continued tracking of the success rate
associated with CHC treatments.
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